Literature DB >> 30952718

Delivery of Antisense Oligonucleotide LOR-2501 Using Transferrin-conjugated Polyethylenimine-based Lipid Nanoparticle.

Bin Zheng1, Shuang Yang2, Qingping Tian1, Yin Xie1, Shuqiu Zhang3, Robert J Lee4,5.   

Abstract

BACKGROUND/AIM: Efficient delivery of antisense oligonucleotide (ASO) by nanoparticle vectors is critical for its clinical application. The aim of this study was to design and evaluate a novel ASO vector TPSH-LP consisting of a reduction-sensitive cationic polymer PEI-SS-HA (PSH), lipids and transferrin (Tf) as a targeting ligand.
MATERIALS AND METHODS: PSH was synthesized based on PEI 25 kDa. Nanoparticles containing PSH and Tf (TPSH-LP) were prepared and used to deliver an ASO LOR-2501 targeting ribonucleotide reductase R1. The physical and chemical properties of TPSH-LP and cellular uptake in HepG2 cells were studied.
RESULTS: TPSH-LP formed a complex with LOR-2501 (L-TPSH-LP) which showed suitable particle size (267.77±16.20 nm) and zeta potential (4.87±0.52 mV). TPSH-LP showed lower cytotoxicity and higher transfection efficiency than PEI 25 kDa in HepG2 cells. The addition of Tf enhanced the targeting and delivery efficiency of PSH-LP. TPSH-LP transported LOR-2501 and down-regulated the levels of R1 protein efficiently by 64.15%.
CONCLUSION: Data demonstrated the potential utility of TPSH-LP for oligonucleotide delivery in cancer therapy. Copyright
© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Polyethylenimine; cancer; lipid nanoparticles; oligonucleotide; transferrin

Mesh:

Substances:

Year:  2019        PMID: 30952718     DOI: 10.21873/anticanres.13285

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

Review 1.  The blood-tumour barrier in cancer biology and therapy.

Authors:  Patricia S Steeg
Journal:  Nat Rev Clin Oncol       Date:  2021-07-12       Impact factor: 66.675

Review 2.  Progress in the Use of Antisense Oligonucleotides for Vaccine Improvement.

Authors:  Alexander Batista-Duharte; Luis Sendra; Maria José Herrero; Damiana Téllez-Martínez; Iracilda Zeppone Carlos; Salvador Francisco Aliño
Journal:  Biomolecules       Date:  2020-02-17

3.  Delivery of antisense oligonucleotide using polyethylenimine-based lipid nanoparticle modified with cell penetrating peptide.

Authors:  Shuang Yang; Dandan Wang; Yaojun Sun; Bin Zheng
Journal:  Drug Deliv       Date:  2019-12       Impact factor: 6.419

Review 4.  Modification of Lipid-Based Nanoparticles: An Efficient Delivery System for Nucleic Acid-Based Immunotherapy.

Authors:  Chi Zhang; Yifan Ma; Jingjing Zhang; Jimmy Chun-Tien Kuo; Zhongkun Zhang; Haotian Xie; Jing Zhu; Tongzheng Liu
Journal:  Molecules       Date:  2022-03-17       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.